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Abstract: The purpose of this study was to establish a model of delayed type 
hypersensitivity (DTH) reaction in the ear skin of large animals such as adult Yucatan pigs, 
which may aid in evaluating the efficacy of therapeutic modalities of newly developed 
anti-inflammatory drugs. The pigs were sensitized with oxazolone, re-challenged with the 
same irritant six days later, and dosed with either vehicle or with cyclosporine A (CsA) 
before and after challenge. CsA reduced the redness, inhibited the accumulation of ear 
fluid and inflammatory cells, as well as the release of the inflammatory mediators. Further, 
CsA inhibited the proliferation of T cells collected from the spleens or PBMCs of   
CsA-treated pigs when these cells were stimulated in vitro with PMA plus Ionomycin. 
These results indicate that pig skin can be used to evaluate modalities for the purpose of 
developing drugs that may be used to treat DTH in humans. 
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1. Introduction  
 
Hypersensitivity refers to an inappropriate or exaggerated adaptive immune response which results 
in tissue damage. There are four main types of hypersensitivity reactions. Delayed type 
hypersensitivity (DTH) is a cell mediated process known as type IV. This reaction has been 
extensively studied in rodents, and multiple drugs for potentially inhibiting this reaction have been 
examined. These include cyclosporine A “CsA” [1], selectin antagonist [2], TAK-427 [3], the 
immunosuppressant drug periplocoside [4], N-acetyl-L-cysteine and N,N’-diacetyl-L-cystine [5], and 
the inhibitor of S-adenosyl-L-homocysteine, DHCaA [6]. However, due to the genetic differences 
among rodents and humans, the need to develop an in vivo model closer to humans is highly desirable 
in order to screen molecules for their immunosuppressive, anti-inflammatory and clinical applications. 
Pigs are genetically closer to humans and have been used for xenotransplantation purposes among 
porcine and baboons or humans, as well as other species [7–11]. 
CsA binds cyclophilin and inhibits the activity of the protein phosphatase calcineurin, resulting in 
an inhibition of T cell function [12]. It also inhibits DTH reactions in mice [1], but whether it has any 
effect on DTH reactions in large animals has not been extensively studied. Here, we successfully 
developed a DTH reaction in the ear skin of other animals, i.e., Yucatan pigs, utilizing the irritant 
oxazolone (4-methoxymethylene-2-phenyl-2-oxazolin-5-one) which has been used to induce atopic 
dermatitis in mice [13], and DTH in rats [14]. Also, we examined the effects of CsA in inhibiting 
inflammatory and cellular events associated with DTH reactions induced by oxazolone. The purpose of 
developing this system is to aid pharmaceutical companies to examine the efficacy of   
anti-inflammatory drugs in large animals that may relate to humans more closely than rodents. Also, 
the system could perhaps provide information that can be utilized to develop new drugs and other 
procedures for potential therapy. 
 
2. Materials and Methods 
 
2.1. Animals 
 
Six-month old, male Yucatan pigs (~25 kg), HLA-matched, were obtained from S&S Farms 
(Escondido, CA, USA). The animals were group-housed under recommendations detailed in the 
DHEW guide for the care and use of laboratory animals (NIH) and according to USDA regulations. 
All procedures were subject to IACUC review. Each animal was trained to tolerate placement in a 
restraining sling for up to 30 min. Training involved the daily placement of the animals in the sling for 
increasing periods of time over 10 days.  
 
2.2. Sensitization and challenging pigs with oxazolone 
 
Pigs were sensitized by the epidermal injections of 2% oxazolone (1 mL total given at ~15 sites) at 
a localized area on the back of each pig. Test animals were challenged on day 6 by the intra-dermal 
injection with 1 mL of 1% oxazolone in acetone: olive oil into the left ear of each pig at about 15 sites. 
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2.3. Other procedures 
 
Animals were lightly sedated with ketamine/xyalazine and placed in the restraining sling. CsA 
(Sandoz Pharmaceuticals, Princeton, NJ, USA), was administered through a feeding tube designed for 
foals. The utilization of oxazalone as an irritant was based on work done in the mice [15]. The 
procedures for dosing the pigs are summarized in Table 1. Red blood cells were lysed by resuspending 
the pelleted splenocytes in 155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA (Sigma-Aldrich,  
St. Louis,  MO, USA) and incubating at room temperature for 5 min with gentle agitation. After 
repeating the red blood cell lysis a second time, the cells were centrifuged and resuspended at a 
concentration of 5 × 10
6/mL in RPMI containing 10% fetal bovine serum. The cells were labeled by 
culturing with 5 µg/mL calcein AM (TefLabs, Capitol View Drive Austin, TX, USA) for 45 min. Ear 
biopsies were placed in HBSS (w/1.21 mM CaCl2, 0.493 mM MgCl2, 0.407 mM MgSO4) containing 
10% FBS (HBSS/FBS). The dorsal and ventral leaflets of the ears were separated and then deposited 
(medial dermis aspects face down) on 1 mg/mL dispase/collagenase (Sigma-Aldrich) in HBBS/BSA. 
The tissue was digested at 37 
oC for 1 h, after which the media was collected. The media was 
centrifuged at 1,000× g for 10 min and the cellular contents resuspended in 200 µL of PBS. The 
recovered cells were placed into a well of a 96 well plate and the fluorescence at an excitation 
wavelength of 480 nm and emission wavelength of 530 nm measured in a Cytofluor 4000 (PerSeptive 
BioSystems, American laboratory Trading, Inc., East Lyme, CT, USA). The number of recovered cells 
from each ear was calculated from a standard curve generated from dilutions of the reserved aliquot of 
the labeled cell suspensions. The ears were dissected and pictures of the dermal inflammation taken.  
 
Table 1. Summary of the protocols used to sensitize and dose the pigs. 
Protocol for pigs in group 1 
Day 0: Intra-dermal sensitization with 2% oxazolone on back 
Day 6, -12 hr: Bled (interleukin-2 (IL-2), interleukin-8 (IL-8), macrophage inflammatory pretin-1 (MIP-1), 
and C-reactive protein (CRP) levels were measured); dosed (PO)  
Day 6, 0 hr: Epi-dermal challenged with 1% oxazolone on ear  
Day 6, +3 hr: Dosed (PO) 
Day 6, +6 hr:  Bled (IL-2, IL-8; MIP-1, and CRP levels were measured) 
Day 6–8: Pigs were sacrificed. Inflamed ears were drained, left and right ears were harvested and pictures taken. 
Protocol for pigs in group 2 
Day 0: Intra-dermal sensitization with 2% oxazolone on back 
Day 6, -12 hr: Bled (IL-2, IL-8; MIP-1, and CRP levels were measured); dosed (PO)  
Day 6, 0 hr: Epi-dermal challenge with 1% oxazolone on the ears  
Day 6, +2 hr: Spleens were harvested from sensitized donor pigs  
Day 6, +3 hr: Dosed (PO)  
Day 6, +6 hr: Bled (IL-2, IL-8; MIP-1, and CRP levels are measured); Injected (IV) with fluorescently labeled 
splenocytes  
Day 6, +9hr: Pigs were sacrificed. Inflamed ears were drained (IL-2 level was measured, and the number of 
cells were calculated). Left and right ears were dissected and pictures taken. Dermis was dissected for 
measuring fluorescence intensity. 
Spleens were harvested (cell isolation and T cell proliferation after PMA/IONO stimulation was conducted), 
blood was collected (IL-2, IL-8; MIP-1, CRP levels were measured). Toxins 2009, 1 
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2.4. Measurement of inflammatory mediators 
 
The levels of porcine IL-2, IL-8, and CRP were assessed using commercial ELISA kits (Bio-Quant, 
Inc., San Diego, CA, USA).  
 
2.5. T cell Proliferation and IL-2 release 
 
Peripheral blood mononuclear cells (PBMCs) and spleens were aseptically removed from the pigs, 
and were subjected to density gradient centrifugation on Histopaque (Sigma-Aldrich). The lymphocyte 
layers were washed twice and resuspended in RPMI 1640. T cell preparations were centrifuged, 
resuspended in 5 mL of incomplete RPMI and counted using a hemocytometer. For T cell 
proliferation, these cells (1 × 10
5/mL) were incubated with 200 ng/mL each of phorbol myristate 
acetate (PMA) and ionomycin (IONO) (Sigma-Aldrich) in complete RPMI media. Two hundred µL of 
complete RPMI containing 0.86 mg/mL thiazolyl blue tetrazolium bromide (MTT, Sigma-Aldrich) 
was added to each well and the plates cultured for an additional 4 h. The plates were centrifuged again, 
the media removed and the well contents solubilized in 100% DMSO. The optical density at 560 nm of 
each well was determined and the average mean of the duplicate wells calculated. The background OD 
560 value, determined from control wells receiving media containing no MTT, was subtracted from 
these values and the data normalized to that of the control wells. Similar to T cell proliferation, both 
PBMCs and splenocytes were removed from the animals and activated with 200 ng/mL each of PMA 
plus IONO in complete RPMI media. After culturing for 24–72 h, the plates were centrifuged at   
1200 rpm for 10 min and the culture supernatants removed and saved. IL-2 levels were measured by 
ELISA assay. 
 
2.6. Statistical analysis 
 
Statistical significance between treated groups and the vehicle control was evaluated by paired t-test 
using the GraphPad Prizm program (GraphPad
 Software, San Diego, CA, USA). Differences between 
groups were considered
  significant at the level of p < 0.05. Percent inhibition was calculated as   
100-values in the presence of CsA divided by values in the presence of vehicle. 
 
3. Results 
 
The results of this study are divided into two parts. The first part will present data obtained from 
pigs in group 1, and the second will present data obtained from pigs in group 2. 
 
3.1. Effect of CsA on the ear inflammation of pigs in group 1 
 
Results in Figure 1 indicate that in three different experiments, the ears of the vehicle pigs (# 53, 
191 and 27) sensitized with oxazolone at day 0 and then challenged on day 6 with the same antigen, 
are highly inflamed, with clear erythema and redness (yellow circles). Figure 1 also shows an obvious 
reduction of these activities in pigs that received 60 mg/kg × 2 CsA (pigs #54, 189 and 28; yellow Toxins 2009, 1 
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circles). Of note, 60 mg/kg CsA was chosen because its availability in the animals is lower than that 
observed in humans, hence a higher dose was used to ensure therapeutic levels. As a control, we also 
monitored inflammation in the right ears of pigs which were only sensitized but not challenged with 
the antigen. Notably, the right ears did not show any clear signs of inflammation. Similarly, there was 
no effect of CsA on the appearance of the right ears.  
 
Figure 1. Effect of treatment with CsA on ear redness of pigs in group 1. (A) Left ears 
were isolated from vehicle (sensitized and challenged) pigs, or pigs dosed PO twice with 
60 mg/kg CsA. Red inflammation where injections were done is shown inside yellow 
circles. The results from three different pigs are shown. (B) Right ears were isolated from 
pigs that were only sensitized but not challenged. 
 
 
3.2. Effect of CsA on inflammatory reactions in inflamed ears 
 
Inflammation is associated with the accumulation of fluids and leukocytes [16]. We entertained the 
possibility that the anti-inflammatory/immunosuppressant compound CsA may have adverse effects on 
such accumulation. For these results and all others, percent inhibition as compared to the controls is 
shown. Results in Figure 2A demonstrate that ear fluid accumulating in inflamed ears was inhibited in 
pigs dosed with CsA, and this inhibition was significant (P < 0.01). The number of total cells (which 
include RBCs and WBCs, designated cell before lysis or “CBL”), accumulating in inflamed ears was 
also inhibited in pigs dosed with CsA, and this inhibition was statistically significant (P < 0.001). 
Similarly, when RBCs were lysed, the number of leukocytes accumulating in the inflamed ears 
(designated cells after lysis or “CAL”), was significantly reduced in the ears of pigs that received this Toxins 2009, 1 
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drug (P < 0.01, Figure 2A). The levels of CRP, IL-2 or IL-8 secreted in the ears of pigs treated with 
CsA were also significantly reduced (P < 0.05, P < 0.05, and P < 0.01, respectively, as shown in  
Figure 2A). Collectively, these results strongly indicate that CsA has a profound anti-inflammatory 
effect toward the inflammation occurring in sensitized and challenged ears of the pigs. 
 
Figure 2. Effect of dosing with CsA on various inflammatory and cellular activities of pigs 
in group 1. Pigs were sensitized and challenged with oxazolone and were either treated 
with vehicle or with 60 mg/kg CsA twice. (A) Percent inhibition after CsA treatment as 
compared to the vehicle is shown as mean ± SEM collected from three pigs. Shown is the 
inhibition of ear fluid, number of cells before RBC lysis (CBL), cells after RBC lysis 
(CAL), CRP, IL-2 and IL-8 levels in sensitized ears after CsA treatment. (B) Percent 
inhibition of the levels of CRP, IL-2, and IL-8 in the serum 6, 9, and 24 h post dosing with 
CsA is shown. (C) Percent inhibition after CsA dosing of T cell proliferation and their 
ability to secrete IL-2 collected from PBMCs that were either unstimulated or stimulated in 
vitro with PMA plus IONO is shown. (D) Percent inhibition after CsA dosing of T cell 
proliferation and their ability to secrete IL-2 collected from spleens that were either 
unstimulated or stimulated in vitro with PMA plus IONO. , P < 0.05, , P < 0.01, ,  
P < 0.001, , P < 0.0001. 
 
 
Next, we examined the effect of dosing pigs with CsA on the release of the inflammatory molecules 
in the serum, which are responsible for the inflammatory response. Results in Figure 2B demonstrate 
that dosing with CsA significantly inhibited the levels of serum CRP after 6, 9 or 24 h of dosing  
(P < 0.001, P < 0.05, and P < 0.001, respectively). Dosing twice with this drug also reduced the level 
of serum IL-2. Notably, this activity did not reach statistical significance after 6 or 24 h, but the 
inhibition was significant after 9 h of dosing (P < 0.05, Figure 2B). Furthermore, dosing with CsA Toxins 2009, 1 
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showed a trend toward reducing the accumulation of the inflammatory chemokine IL-8 in the serum of 
dosed pigs after 6 or 9 h, and this reduction reached statistical significance after 24 h of dosing   
(P < 0.05, Figure 2B). The ability CsA to affect various activities of T cells in vitro was next 
investigated. First, we examined whether PBMCs isolated from pigs sensitized and challenged with 
oxazolone but no CsA, or from pigs dosed as above but also treated with CsA, can be activated in 
vitro. Results shown in Figure 2C indicate that cells isolated from pigs dosed with CsA were inhibited 
from proliferating upon stimulation with PMA plus IONO for 72 h. Similar to PBMCs, cells isolated 
from the spleens of pigs dosed with CsA had significantly lower proliferation than T cells isolated 
from vehicle-treated pigs, upon stimulation with PMA plus IONO (P < 0.05, Figure 2D). 
In addition, both spontaneous release of IL-2 (without in vitro stimulation) and that released upon 
stimulating PBMCs of CsA dosed pigs with PMA plus IONO for 48 h in vitro were significantly 
inhibited (P < 0.0001, and P < 0.001, respectively, as shown in Figure 2C). In the spleens, the 
inhibitory effect of CsA on IL-2 secretion was clearly noted after 48 h activation with PMA plus IONO 
(P < 0.01, Figure 2D). 
 
3.3. Effect of CsA on the ear inflammation of pigs in group 2 
 
Pigs in group 2 provide excellent model to monitor the accumulation of inflammatory cells at sites 
of inflammation. There was an obvious reduction in the redness of the ears in pigs that received twice 
60 mg/kg CsA (pigs #38 and 90). Similar to pigs in group 1, the inflammation in the right ears was 
also monitored, which did not show any clear sign of inflammation (Figure 3). 
 
Figure 3. Effect of CsA treatment on ear inflammation of pigs in group 2. (A) Left ears 
were isolated from pigs that were sensitized and challenged with oxazolone, and were 
dosed with either vehicle or with 60 mg/kg CsA twice. Red inflammation where injections 
were done is shown inside yellow circles. (B) Right ears were isolated from pigs that were 
only sensitized but not challenged with oxazolone. 
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In addition, we investigated the migration of cells isolated from pigs that were sensitized with the 
antigen. These cells were labeled with calcein AM and injected IV into vehicle pigs or pigs treated 
with the different compounds. Results in Figure 4A demonstrate that the amount of ear fluid (EF) 
recovered from pigs dosed with CsA was highly inhibited (P < 0.0001); whereas about 10 mL of EF 
were recovered from control pigs, less than 2 mL were obtained from pigs treated with CsA. The 
fluorescence units (FU) recovered from the ears of CsA-treated pigs was also inhibited when compared 
to the FU recovered from vehicle pigs (P < 0.01). Similarly, there was a significant inhibition of the 
migration of sensitized fluorescently labeled T cells (FC) into the sites of inflammation in pigs treated 
with CsA (P < 0.01, Figure 4A). 
 
Figure 4. Effect of dosing with CsA on T cell activities of pigs in group 2. Pigs were 
sensitized and challenged with oxazolone, and were either treated with vehicle or with 60 
mg/kg CsA twice. (A) Percent inhibition after CsA treatment as compared to the vehicle is 
shown as mean ± SEM. The inhibition of ear fluid, fluorescent units (FU), and the recovery 
of fluorescent cells (FC) in sensitized ears after CsA treatment is shown. (B) Shown is the 
percent inhibition of the number of cells before RBC lysis (CBL), cells after RBC lysis 
(CAL), CRP level and IL-8 levels in sensitized ears, is shown. (C) Percent inhibition after 
CsA dosing of serum IL-8 and IL-2 levels 6 and 9 h after dosing with CsA (24 h samples 
were not collected). (D) Percent inhibition after CsA dosing of T cell proliferation and their 
ability to secrete IL-2 collected from PBMCs that were either non-stimulated or stimulated 
in vitro with PMA plus IONO. , P < 0.05, , P < 0.01, , P < 0.001, , P < 0.0001. 
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Similar to the approach of the first model, we investigated the possibility that CsA may ameliorate 
DTH by inhibiting the release of inflammatory mediators. The number of total cells (which include 
RBCs and WBCs; cells before lysis “CBL”), accumulating in inflamed ears was significantly reduced 
in pigs dosed with CsA (P < 0.05). Similarly, when RBCs were lysed, the number of leukocytes (cells 
after RBC lysis or “CAL”), accumulated in inflamed ears was significantly inhibited in pigs dosed 
with CsA (P < 0.05, Figure 4B). Further, we examined the release of the inflammatory molecules 
normally secreted in inflamed ears, which are responsible for the inflammatory response occurring at 
these sites. Dosing with CsA significantly inhibited the levels of CRP (P < 0.0001), and the 
inflammatory chemokine IL-8 in inflamed ears (P < 0.01), as shown in Figure 4B. 
The effect of CsA on the levels of the inflammatory molecules released in the serum was next 
examined. Hence, the levels of IL-2 and IL-8 in the serum of pigs dosed with CsA were measured and 
compared to the levels of these molecules in vehicle control pigs. Results in Figure 4C demonstrate 
that the amount of serum IL-8 in CsA-dosed pigs was significantly inhibited 6 and 9 h post dosing  
(P < 0.05 and P < 0.001, respectively). Similar findings were observed when the level of serum IL-2 
was measured, i.e. there was a significant reduction of IL-2 released in the serum of CsA-dosed pigs 
after 6 and 9 h of dosing (P < 0.01, and P < 0.05, respectively, Figure 4C). 
The ability of CsA to affect various activities of T cells in vitro was investigated. First, we 
examined whether PBMCs isolated from pigs in the vehicle control or from pigs dosed with CsA are 
activated in vitro. The results show that cells isolated from pigs dosed with CsA were inhibited from 
proliferating, even in the absence of any stimulus (P < 0.01). Upon stimulation with PMA plus IONO 
for 72 h, it is clear that cells isolated from pigs treated with CsA had significantly much lower 
proliferation than cells isolated from vehicles (P < 0.01, Figure 4D). The ability of CsA to affect IL-2 
release from PBMCs was next examined. Notably, PBMCs isolated from pigs treated with CsA had 
lower IL-2 release when compared to the vehicle control after 48 h in vitro incubation with or without 
stimulation with PMA plus IONO (P < 0.01, and P < 0.0001, respectively, Figure 4D).  
 
4. Discussion 
 
DTH, a Th1 reaction, is characterized by elicitation of immune response after antigenic stimulation 
and then re-challenging with the same antigen. However, no response can be detected after only the 
sensitization step [16]. During DTH, sensitized T cells migrate toward the sites of antigenic 
stimulation manifesting cellular responses which include the release of Th1 cytokines such as IL-2 and 
IFN-. Other cell types such as neutrophils are also recruited to these sites, but these cells migrate 
earlier than T cells. One important function of these cells is secreting cytokines and chemokines which 
activate T cells and amplify the reaction by recruiting more T cells and antigen presenting cells to the 
sites of action [16]. In pigs, CD4
+, CD8
+ and 
 T cells were recruited into inflamed sites [17]. Other 
chemoattractants accumulate at sites of inflammation and also recruit various subsets of   
lymphocytes [18,19]. 
Although allergic contact dermatitis was previously established in Gottingen pigs using   
2,4-dinitrofluorobenzene (DNFB) as a hapten [17], this study did not examine the effect of CsA on 
contact dermatitis or validate the model as a non-rodent model for drug discovery. Here we 
successfully established DTH in the ear skin of adult Yucatan pigs. Further, our approach of injecting Toxins 2009, 1 
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fluorescently labeled sensitized cells into challenged pigs adds another important parameter of 
examining the infiltration of sensitized cells into inflamed sites. This is important since most DTH 
reactions have been previously examined in mice and rats. However, most of the small molecules 
which are the basis for non biological drugs that include ion channel inhibitors and G protein-coupled 
receptor antagonists do not cross react with mice or rats. Hence, there is a need not only to develop but 
also to validate such inflammation models in large non rodent animals such as the pig system. The 
importance of our findings rests in the relatedness of pigs to humans in terms of genetic background 
and immunological reactions. 
Our results indicate that oxazolone successfully induced inflammation in pigs as determined by ear 
swelling, redness and erythema that occurred in the challenged ears, which is similar to the effect of 
this irritant in mice and rats [13-15]. Orally administered CsA robustly reduced the extent of 
inflammation in the challenged ears. In addition dosing pigs with this drug significantly inhibited the 
accumulation of ear fluid and inflammatory cells in inflamed ears. It also inhibited the accumulation 
and/or the release of the inflammatory mediators CRP, IL-2 and IL-8 in inflamed ears. This clearly 
shows an important role of CsA as an anti-inflammatory drug which inhibits the accumulation of 
inflammatory cells secreting inflammatory mediators such as IL-2. The fact that CsA also reduced IL-8 
release at the sites of inflammation strongly indicates that neutrophils are impeded from migrating into 
these sites since IL-8 is a robust chemoattractant for these cells [19]. 
The effect of CsA goes beyond inflammatory sites (ears), as this drug also inhibited the release of 
IL-2, IL-8 and CRP in the serum of dosed pigs in both pig models. The systemic effects of CsA 
indicates that inflammatory cells that are generated after initial sensitization are found at body sites 
such as blood circulation and that the activity of CsA ensures that these inflammatory cells are 
inhibited from secreting inflammatory mediators. Not only the release of inflammatory mediators in 
the circulation is inhibited, but also the proliferation of T cells is impeded after dosing with CsA, 
which could be due to the immunosuppressive effect of CsA. This is true for PBMCs and splenic T 
cells. The anti-proliferative effect of CsA is more pronounced when T cells were stimulated in vitro 
with PMA plus IONO. Dosing with CsA also inhibited T cells collected from PBMCs or spleens from 
secreting the inflammatory cytokine IL-2. Collectively, these results show that PO dosing with CsA 
results in a potent anti-inflammatory effect for DTH reactions both at inflamed sites as well as at distal 
sites ensuring no Th1 response is taking place. However, one can not exclude the possibility of 
immunosuppressant effects of CsA, as has been shown in rodents [20]. It should be also mentioned 
that the inhibitory effects of CsA in the sensitization phase of hypersensitivity have been well 
documented [21,22]. Finally, our results support the notion that pigs can be used as a model to screen 
anti-inflammatory compounds for the purpose of generating drugs that may be used to treat DTH 
reactions in human.  
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